Quick Answer
Pulmonx Corp reported Cash and Equivalents of $69.75 million for fiscal year 2025.
Pulmonx Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $69.75M | -1.6% |
| 2024 | $70.91M | -15.1% |
| 2023 | $83.55M | -17.9% |
| 2022 | $101.74M | -31.5% |
| 2021 | $148.48M | -35.9% |
| 2020 | $231.56M | +1468.1% |
| 2019 | $14.77M | +258.1% |
| 2018 | $4.12M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $76.55M | +20.9% | +1.4% |
| June 30, 2025 | $75.47M | +18.9% | +1.2% |
| March 31, 2025 | $74.56M | +6.3% | +5.1% |
| December 31, 2024 | $70.91M | -15.1% | +12.0% |
| September 30, 2024 | $63.31M | -33.3% | -0.2% |
| June 30, 2024 | $63.46M | -37.5% | -9.5% |
| March 31, 2024 | $70.16M | -36.5% | -16.0% |
| December 31, 2023 | $83.55M | -17.9% | -12.0% |
- Pulmonx Corp showed a decrease of -1.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Pulmonx Corp’s cash and equivalents has grown by 1591.3% (from $4.12 million to $69.75 million).
- The most recent figure is from Pulmonx Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: